Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
NdqJ4tzEVBhqnEFs
